目次

Executive Summary
Market overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Application
Market segments
Comparison by Application
Gastrointestinal disorders - Market size and forecast 2020-2025
Infectious diseases - Market size and forecast 2020-2025
Others - Market size and forecast 2020-2025
Market opportunity by Application

Customer landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape
Market drivers
Market challenges
Market trends

Vendor Landscape
Overview
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
4D pharma Plc
ENTEROME SA
Ferring B.V.
Johnson and Johnson Inc.
Kaleido Biosciences Inc.
OptiBiotix Health Plc
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc.
Takeda Pharmaceutical Co. Ltd.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Application - Market share 2020-2025 (%)
22: Comparison by Application
23: Gastrointestinal disorders - Market size and forecast 2020-2025 ($ million)
24: Gastrointestinal disorders - Year-over-year growth 2020-2025 (%)
25: Infectious diseases - Market size and forecast 2020-2025 ($ million)
26: Infectious diseases - Year-over-year growth 2020-2025 (%)
27: Others - Market size and forecast 2020-2025 ($ million)
28: Others - Year-over-year growth 2020-2025 (%)
29: Market opportunity by Application
30: Customer landscape
31: Market share By Geographical Landscape 2020-2025 (%)
32: Geographic comparison
33: North America - Market size and forecast 2020-2025 ($ million)
34: North America - Year-over-year growth 2020-2025 (%)
35: Europe - Market size and forecast 2020-2025 ($ million)
36: Europe - Year-over-year growth 2020-2025 (%)
37: Asia - Market size and forecast 2020-2025 ($ million)
38: Asia - Year-over-year growth 2020-2025 (%)
39: ROW - Market size and forecast 2020-2025 ($ million)
40: ROW - Year-over-year growth 2020-2025 (%)
41: Key leading countries
42: Market opportunity By Geographical Landscape ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: 4D pharma Plc - Overview
50: 4D pharma Plc - Product and service
51: 4D pharma Plc - Key offerings
52: 4D pharma Plc - Key customers
53: 4D pharma Plc - Segment focus
54: ENTEROME SA - Overview
55: ENTEROME SA - Product and service
56: ENTEROME SA - Key offerings
57: ENTEROME SA - Key customers
58: ENTEROME SA - Segment focus
59: Ferring B.V. - Overview
60: Ferring B.V. - Product and service
61: Ferring B.V. - Key offerings
62: Ferring B.V. - Key customers
63: Ferring B.V. - Segment focus
64: Johnson and Johnson Inc. - Overview
65: Johnson and Johnson Inc. - Business segments
66: Johnson and Johnson Inc. - Key offerings
67: Johnson and Johnson Inc. - Key customers
68: Johnson and Johnson Inc. - Segment focus
69: Kaleido Biosciences Inc. - Overview
70: Kaleido Biosciences Inc. - Product and service
71: Kaleido Biosciences Inc. - Key offerings
72: Kaleido Biosciences Inc. - Key customers
73: Kaleido Biosciences Inc. - Segment focus
74: OptiBiotix Health Plc - Overview
75: OptiBiotix Health Plc - Product and service
76: OptiBiotix Health Plc - Key offerings
77: OptiBiotix Health Plc - Key customers
78: OptiBiotix Health Plc - Segment focus
79: PureTech Health Plc - Overview
80: PureTech Health Plc - Business segments
81: PureTech Health Plc - Key offerings
82: PureTech Health Plc - Key customers
83: PureTech Health Plc - Segment focus
84: Second Genome Therapeutics - Overview
85: Second Genome Therapeutics - Product and service
86: Second Genome Therapeutics - Key offerings
87: Second Genome Therapeutics - Key customers
88: Second Genome Therapeutics - Segment focus
89: Seres Therapeutics Inc. - Overview
90: Seres Therapeutics Inc. - Product and service
91: Seres Therapeutics Inc. - Key offerings
92: Seres Therapeutics Inc. - Key customers
93: Seres Therapeutics Inc. - Segment focus
94: Takeda Pharmaceutical Co. Ltd. - Overview
95: Takeda Pharmaceutical Co. Ltd. - Product and service
96: Takeda Pharmaceutical Co. Ltd. - Key offerings
97: Takeda Pharmaceutical Co. Ltd. - Key customers
98: Takeda Pharmaceutical Co. Ltd. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations